This article is more than 5 years old. Information may no longer be current.

EyeGate reports $3.3 million loss in second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals reported a net loss of $3.3 million in the second quarter of 2017 compared with a net loss of $3.8 million in 2016’s second quarter, according to a press release.

Research and development costs decreased from $2.5 million to $2.3 million due to reduced activity in the company’s phase 3 anterior uveitis treatment trial.

General and administrative expenses also decreased from $1.6 million in 2016’s second quarter to $1.2 million this year, which was attributed to decreases in corporate and professional fees.

EyeGate reported cash and cash equivalents of $11.8 million as of June 30.